Activity Description
The incidence of acute myeloid leukemia (AML) has increased due to an aging population, risk from environmental exposures, and treatment-related/secondary AML in survivors of young and childhood cancers. Members of the hematology/oncology care team are challenged to keep apprised of clinical data, incorporate novel agents into their clinical practice, and manage side effects of newer therapies. In this activity, Dr Daniel Pollyea and Dr Amer Zeidan provide expert commentary on 2 challenging clinical case scenarios focused on management of AML.
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc., and Spire Learning. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: American Academy of CME, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners/Nurses: The Academy designates this educational activity for 0.75 ANCC contact hours (0.7 pharmacotherapeutic contact hours).
Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Instructions on how to receive CME/CE Credit
There is no fee to participate in this activity. In order to receive your CME/CNE certificate, you must:
-
Complete mechanisms the preassessment questions
-
Participate in the activity
-
Complete the postassessment and evaluation
Your certificate will be available upon completion of the activity.
Learning Objectives
Upon completion of this activity, learners should be better able to:
-
SUMMARIZE mechanisms of action and safety/efficacy data of novel approved agents for AML
-
CREATE individualized assessment and treatment plans as a team for individuals with AML
-
IDENTIFY appropriate adverse event monitoring and supportive care strategies for individuals with AML
-
EVALUATE how measurable residual disease (MRD) assessment can be used in AML management
Faculty
Daniel A. Pollyea, MD, MS
Associate Professor of Medicine
Division of Hematology
Clinical Director of Leukemia Services
Robert H. Allen, MD, Endowed Chair in Hematology Research
University of Colorado School of Medicine
Aurora, CO
Faculty Biography
Daniel A. Pollyea, MD, MS
Dr Daniel A. Pollyea is an Associate Professor of Medicine in the Division of Hematology, Clinical Director of Leukemia Services, and the Robert H. Allen, MD, Endowed Chair in Hematology Research at the University of Colorado School of Medicine in Aurora, Colorado. He earned his medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing an internal medicine residency at the University of Chicago Hospitals and a fellowship in hematology/oncology at Stanford University in California.
Dr Pollyea's research interests include understanding the nature of leukemia stem cells and developing novel therapies for leukemia and other hematologic malignancies through collaborative laboratory-based efforts and clinical trials. He has been principal investigator on several clinical trials, and his work has led to multiple presentations at national and international conferences. He has also published over 80 manuscripts in peer-reviewed journals. Additionally, Dr Pollyea is a Leukemia & Lymphoma Society Scholar in Clinical Research and was recently awarded the Chairman's Quality of Life Award by the Leukemia & Lymphoma Society Rocky Mountain Chapter.
Disclosure Statement
Advisory Board – for scientific information: AbbVie Inc; Agios, Inc; Celgene Corporation; Daiichi-Sankyo Company, Ltd; Forty Seven Inc; Janssen Pharmaceuticals, Inc; Pfizer Inc; Takeda Pharmaceutical Company Ltd
Consultant – for marketing purposes: AbbVie Inc; Celgene Corporation
Grant Recipient/Research Support: AbbVie Inc
Faculty
Amer M. Zeidan, MBBS, MHS
Associate Professor of Medicine, Hematology
Yale University
New Haven, CT
Faculty Biography
Amer M. Zeidan, MBBS, MHS
Amer M. Zeidan, MBBS, MHS, is an Associate Professor of Medicine (Hematology) at Yale University. He completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University, where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr Zeidan received his MBBS degree from the Faculty of Medicine, University of Jordan, Amman, before completing his internal medicine residency at Rochester General Hospital in New York.
Dr Zeidan specializes in the management of myeloid malignancies, especially acute myeloid leukemia (AML) and MDS, and is a nationally and internationally recognized expert in these malignancies. The focus of his clinical/translational research is the development of novel therapies for AML, MDS, and other myeloid malignancies. He is the principal investigator on several investigator-initiated, cooperative group, and industry-sponsored clinical trials in AML, MDS, and other hematologic malignancies. Dr Zeidan especially focuses on the use of novel therapies and immunotherapy, especially in combination-based approaches for myeloid malignancies. His second area of research interest is effectiveness and outcomes research in hematologic malignancies, a type of research that evaluates how much benefit patients achieve from existing treatments at the real-world community level in comparison to what is seen in the controlled clinical trials setting.
Dr Zeidan has received numerous awards including the American Society of Clinical Oncology Young Investigator Award (ASCO YIA), the Aplastic Anemia and MDS International Foundation (AAMDSIF)/Edward P. Evans Foundation-MDS Clinical Research Consortium Fellowship Award, and the Tito Bastianello Young Investigator Award. He has also received the Leukemia and Lymphoma Society Scholar in Clinical Research and the National Cancer Institute Cancer Clinical Investigator Team Leadership awards. Dr Zeidan has presented his research at multiple national and international meetings. He is an author on more than 160 peer-reviewed publications and book chapters. Dr Zeidan also serves on the editorial board of several important hematology journals and has been an ad hoc reviewer for such prestigious journals as New England Journal of Medicine, Lancet Oncology, Blood, Journal of Clinical Oncology, JAMA Oncology, and others.
Disclosure Statement
Consultant – for clinical trial design: AbbVie; Acceleron Pharma; Agios; Astellas Pharma US, Inc; BeyondSpring Inc; Boehringer Ingelheim; Bristol-Myers Squibb Company, Cardinal Health; Celgene Corporation; Daiichi-Sankyo Company, Ltd; Epizyme; Incyte Corporation; Ionis Pharmaceuticals, Inc; Jazz Pharmaceuticals, Inc; Novartis Pharmaceuticals Corp; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Seattle Genetics, Inc; Taiho Pharmaceutical Group; Takeda; Trovagene, Inc
Grant Receipant/Research Support: AbbVie Inc; ADC Therapeutics; Aprea Therapeutics; Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Company; Celgene Corporation; Incyte Corporation; MedImmune; Novartis Pharmaceuticals Corp; Pfizer Inc; Takeda; Trovagene, Inc
Travel Support: Novartis Pharmaceuticals Corp; Pfizer Inc; Troyagene, Inc
Planning Committee/Faculty Educators
Please refer to the Planning Committee/Faculty Educators section for each faculty member's affiliation and disclosure statement.
Educational Planning Committee
American Academy of CME, Inc.
John JD Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner
No relevant financial relationships with any commercial interests.
Reviewers
Maria Amaya, MD
Grant/Research Support (spouse): Olatec Therapeutics LLC
James Dugan, MD
Promotional Speakers Bureau: AbbVie Inc.
MiKaela Olsen, RNP, APRN-CNS, AOCNS, FAAN
No relevant financial relationships with any commercial interest
Spire Learning
Chad Thompson, Cara U, PharmD, Kate Evans and Michael Marinaro
No relevant financial relationships with any commercial interest
Jeanne Prater
Shareholder (spouse/partner): Johnson & Johnson
Employee (spouse/partner): Novo Nordisk
Theresa Vera
Employee (self-former): Takeda Pharmaceuticals; (spouse/partner): Walgreens
Shareholder: Pfizer
Patient Advocate
Ralph Hills
Shareholder (self/spouse): AbbVie Inc; Agios, Inc; Celgene Corporation
Planning Commitee
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Advisory Board – for scientific information: Daiichi-Sankyo Company, Ltd; Salix Pharmaceuticals; Stemline Therapeutics, Inc
Naval G. Daver, MD
Advisory/Consulting: AbbVie Inc; Agios, Inc; Astellas Pharma US, Inc; Bristol-Myers Squibb Company; Celgene Corporation; Daiichi-Sankyo Company, Ltd; ImmunoGen, Inc; Incyte Corporation; Jazz Pharmaceuticals, Inc; Karyopharm Therapeutics Inc; Novartis Pharmaceuticals Corp; Otsuka America Pharmaceutical, Inc; Pfizer Inc; Sunesis Pharmaceuticals, Inc
Grant Recipient/Research Support: AbbVie Inc; Bristol-Myers Squibb Company; Daiichi-Sankyo Company, Ltd; Genentech, Inc; GlycoMimetics, Inc; ImmunoGen, Inc; Incyte Corporation; Karyopharm Therapeutics Inc; Nohla Therapeutics; Novartis Pharmaceuticals Corp; Pfizer Inc; Servier Pharmaceuticals LLC; Sunesis Pharmaceuticals, Inc
Honoraria: AbbVie Inc; Astellas Pharma US, Inc; Bristol-Myers Squibb Company; ImmunoGen, Inc; Incyte Corporation; Jazz Pharmaceuticals, Inc; Novartis Pharmaceuticals Corp; Otsuka America Pharmaceutical, Inc; Pfizer Inc
Roland B. Walter, MD, PhD, MS
Advisory Board: Amphivena Therapeutics, Inc
Consultant – for clinical trial design: Agios, Inc; Amgen Inc; Aptevo Therapeutics; argenx BVBA; Astellas Pharma US, Inc; BioLineRx Ltd; BiVictriX Therapeutics Ltd; Boehringer Ingelheim Pharmaceuticals, Inc; Boston Biomedical Ltd; Covagen AG; Daiichi-Sankyo Company, Ltd; Jazz Pharmaceuticals, Inc; Kite Pharma, Inc; NewLink Genetics Corp; Pfizer Inc; Race Oncology Ltd
Grant Recipient/Research Support: Agios, Inc; Amgen Inc; Aptevo Therapeutics; Arog Pharmaceuticals, Inc; BioLineRx Ltd; Jazz Pharmaceuticals, Inc; MacroGenics, Inc; Pfizer Inc; Seattle Genetics, Inc; Selvita; Stemline Therapeutics, Inc
Intellectual Property/Patents: Amgen Inc
Shareholder (Stock Options): Amphivena Therapeutics, Inc
Levels of Evidence
Levels of evidence are provided for any patient care recommendations made during this presentation.
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
Each rating is applied to a single reference in the presentation, not the entire body of evidence on the topic.